Results from clinical trials determine the effectiveness, toxicity and, ultimately, the approval of novel therapies for cancer. Here, Gregory Pond, PhD, from McMaster University, Hamilton, ON, discusses the results of two Phase III studies investigating the immune checkpoint inhibitor cabozantinib, COMET-1 and COMET-2. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Pond reviews the rationale, cohort and results of the trial. He ultimately highlights the importance of the presence risk of factors in identifying working novel therapies for cancer.
Could cabozantinib be a successful novel therapy for mCRPC?
